PRESS RELEASE published on 06/24/2024 at 22:05, 2 years 1 month ago CureVac Announces Voting Results of General Meeting CureVac announces voting results of the general meeting, including board appointments and auditor reappointment. Shareholders voted in favor of all proposals Appointments Voting Results General Meeting CureVac Auditor Reappointment
BRIEF published on 05/28/2024 at 13:05, 2 years 2 months ago CureVac Announces Dosing of First Participant in Phase 2 Influenza Study GSK MRNA Technology Phase 2 Study CureVac Influenza Vaccine
BRIEF published on 05/28/2024 at 13:05, 2 years 2 months ago CureVac annonce le dosage du premier participant à l'étude de phase 2 sur la grippe GSK Technologie ARNm Étude De Phase 2 CureVac Vaccin Contre La Grippe
PRESS RELEASE published on 05/28/2024 at 13:00, 2 years 2 months ago CureVac Announces Dosing of First Participant in a Phase 2 Study in Seasonal Influenza; Development in Collaboration with GSK CureVac initiates Phase 2 study in collaboration with GSK for seasonal influenza vaccine, targeting improved immune responses against influenza B strain GSK Vaccine Development Phase 2 Study CureVac Seasonal Influenza
BRIEF published on 05/23/2024 at 13:05, 2 years 2 months ago CureVac Announces Financial Results for the First Quarter of 2024 and Provides Business Update Financial Results Business Update Q1 2024 CureVac FDA Fast Track
BRIEF published on 05/23/2024 at 13:05, 2 years 2 months ago CureVac annonce ses résultats financiers pour le premier trimestre 2024 et fait le point sur ses activités Résultats Financiers Mise À Jour De L'entreprise T1 2024 CureVac Procédure Accélérée De La FDA
PRESS RELEASE published on 05/23/2024 at 13:00, 2 years 2 months ago CureVac Announces Financial Results for the First Quarter of 2024 and Provides Business Update CureVac announces financial results for Q1 2024, reports €300.2 million cash position and updates on organizational restructuring and patent litigations Financial Results Cash Position CureVac Patent Litigation Organizational Redesign
BRIEF published on 04/24/2024 at 13:11, 2 years 3 months ago CureVac Announces 2023 Financial Results and Strategic Business Updates MRNA Technology CureVac Pharmaceutical Collaborations Oncology Vaccines Prophylactic Vaccines
BRIEF published on 04/24/2024 at 13:11, 2 years 3 months ago CureVac annonce ses résultats financiers pour 2023 et des mises à jour stratégiques sur ses activités Technologie ARNm CureVac Collaborations Pharmaceutiques Vaccins Contre L'oncologie Vaccins Prophylactiques
BRIEF published on 04/24/2024 at 13:08, 2 years 3 months ago CureVac Begins Combined Phase 1/2 Study for Avian Influenza H5N1 Vaccine with GSK GSK CureVac Phase 1/2 Study Influenza H5N1 MRNA Vaccine
Published on 08/06/2026 at 15:00, 3 hours 28 minutes ago Norsemont Strategically Expands Choquelimpie Land Package To 9,048 Hectares
Published on 08/06/2026 at 14:30, 3 hours 58 minutes ago Loar Holdings Inc. Reports Q2 2026 Record Results and Upward Revision to 2026 Outlook
Published on 08/06/2026 at 14:30, 3 hours 58 minutes ago NV Gold Announces Expansion of Holdings and Drill Program at the Slumber Gold Project in Nevada
Published on 08/06/2026 at 14:30, 3 hours 58 minutes ago AIAI Holdings' MediGuide Launches Longevity Intelligence, Redefining Personalized Preventive Healthcare
Published on 08/06/2026 at 14:00, 4 hours 28 minutes ago Adcore to Publish Second Quarter 2026 Results on August 13, 2026
Published on 08/06/2026 at 17:20, 1 hour 7 minutes ago Strutt Enters Europe: Expands Product Lineup with New ev¹e Variant and Showcases Evolving Smart Ecosystem at IFA 2026
Published on 08/06/2026 at 16:15, 2 hours 12 minutes ago Monotype and Kittl Expand Partnership To Bring Brand Typography Directly Into Creative Workflows
Published on 08/06/2026 at 15:20, 3 hours 8 minutes ago Form 8.3 - The Vanguard Group, Inc.: SEGRO plc
Published on 08/06/2026 at 17:45, 43 minutes ago Declaration of voting rights at the end of July 2026
